Connect Biopharma Holdings (CNTB) Total Current Liabilities (2020 - 2026)

Connect Biopharma Holdings has disclosed Total Current Liabilities across 7 years of filings, most recently posting $16.3 million for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 51.76% year-over-year to $16.3 million; the TTM figure through Jun 2026 stood at $16.3 million (up 51.76% YoY), while the FY2025 annual figure was $13.6 million, up 60.87% from the prior year.
• Total Current Liabilities came in at $16.3 million for Q2 2026 at Connect Biopharma Holdings, down from $17.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $25.3 million in Q4 2023 to a low of $8.5 million in Q4 2024.
• Average Total Current Liabilities over 5 years is $14.3 million, with a median of $14.3 million recorded in 2023.
• Year-over-year, Total Current Liabilities plunged 66.54% in 2024 and surged 99.01% in 2026.
• Over 5 years, Total Current Liabilities stood at $15.3 million in 2022, then soared by 65.31% to $25.3 million in 2023, then sank by 66.54% to $8.5 million in 2024, then surged by 60.87% to $13.6 million in 2025, then rose by 19.75% to $16.3 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $16.3 million in Q2 2026, $17.0 million in Q1 2026, and $13.6 million in Q4 2025.